Combo Therapy for Myelodysplastic Syndromes Misses Survival Goal in Randomized Trial

(MedPage Today) — HOUSTON — Survival in untreated, intermediate- and higher-risk myelodysplastic syndromes (MDS) failed to improve with the addition of the targeted agent venetoclax (Venclexta) to chemotherapy, a large randomized trial showed…

Source link : https://www.medpagetoday.com/meetingcoverage/soho/117342

Author :

Publish date : 2025-09-06 17:16:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

Combo Therapy for Myelodysplastic Syndromes Misses Survival Goal in Randomized Trial

Are You Ready for Measles’ Wrath?

Who Needs a Beta-Blocker After a Heart Attack? RSV Vaccines and Hospitalizations

Related Posts

Fracture Protection May Be Another Benefit of GLP-1 Receptor Agonists

Few Long-Term Bone Consequences After Teen Bariatric Surgery

‘I Don’t Know How Many Died’: What We Heard This Week

Osimertinib’s Benefits in NSCLC Can Extend Beyond First Line

Do I Have to Go Abroad for a COVID Booster?

Perioperative Nivolumab Does Not Sacrifice QoL in NSCLC

Fracture Protection May Be Another Benefit of GLP-1 Receptor Agonists

Few Long-Term Bone Consequences After Teen Bariatric Surgery

‘I Don’t Know How Many Died’: What We Heard This Week

Osimertinib’s Benefits in NSCLC Can Extend Beyond First Line

Do I Have to Go Abroad for a COVID Booster?

Perioperative Nivolumab Does Not Sacrifice QoL in NSCLC

High Childhood Blood Pressure May Predict Risk of Early CVD Mortality

What Polls Show About Americans’ Views on Childhood Vaccine Mandates

Categories

Archives